Active, Not Recruiting
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454
- Conditions
- Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
- Locations
-
- Regeneron Investigational Site Birmingham, Alabama, United States
- Regeneron Investigational Site Gilbert, Arizona, United States
- Regeneron Investigational Site Bakersfield, California, United States
- Regeneron Investigational Site Long Beach, California, United States